Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Amortization of Deferred Charges (2019 - 2020)

Akebia Therapeutics (AKBA) has disclosed Amortization of Deferred Charges for 2 consecutive years, with -$647000.0 as the latest value for Q1 2020.

  • On a quarterly basis, Amortization of Deferred Charges fell 5.37% to -$647000.0 in Q1 2020 year-over-year; TTM through Mar 2020 was -$2.3 million, a N/A change, with the full-year FY2019 number at -$2.2 million, changed N/A from a year prior.
  • Amortization of Deferred Charges was -$647000.0 for Q1 2020 at Akebia Therapeutics, down from -$556000.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of -$483000.0 in Q2 2019 to a low of -$647000.0 in Q1 2020.